Chronic lymphocytic leukaemia trials in Israel
10 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleA Clinical Trial of MK-1045 in People With B-cell Cancer (MK-1045-006)
- Where
- Haifa, Jerusalem, Ramat Gan, Tel Aviv
- Age
- 18 years and over
- People
- 60 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT07709000 · EU 2025-522242-49-00 - Phase 3Taking peopleA Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- Where
- Haifa, Jerusalem, Ramat Gan, Tel Aviv
- Age
- 18 years and over
- People
- 735 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT05947851 · EU 2022-501560-17-00 - Phase 1Enrolling by invitationA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Haifa, Jerusalem, Tel Aviv
- Age
- 18 years and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - Phase 4Taking peopleA Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Where
- Tel Aviv
- Age
- 18 years and over
- People
- 150 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07218341 - Phase 2Taking peopleEfficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
- Where
- Afula, Beersheba, Haifa, Jerusalem, Ramat Gan, Rehovot, Tel Aviv
- Age
- 18 years and over
- People
- 490 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT04728893 · EU 2023-504931-42-00 - Phase 3Taking peopleA Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- Where
- Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan, Tsrifin
- Age
- 18 years and over
- People
- 1,200 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136559 · EU 2022-501697-19-01 - Phase 3Taking peopleA Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Where
- Haifa, Jerusalem, KfarSava, Petah Tikva, Ramat Gan, Tel Aviv
- Age
- 18 years and over
- People
- 500 worldwide
- Run by
- BeOne Medicines
See details and how to joinNCT06973187 · EU 2025-522860-34-00 - Phase 3Taking peopleA Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Where
- Jerusalem, Tel Aviv
- Age
- 18 years and over
- People
- 737 worldwide
- Run by
- Loxo Oncology, Inc.
See details and how to joinNCT05254743 · EU 2023-507699-38-00 - Phase 3Taking peopleGlobal Trial in APG2575 for Patients With CLL/SLL
- Where
- Haifa, Jerusalem, Kfar Saba, Tel Aviv
- Age
- 18 years to 99 years
- People
- 400 worldwide
- Run by
- Ascentage Pharma Group Inc.
See details and how to joinNCT06104566 · EU 2023-508005-24-00 - Phase 2Taking peopleStudy to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
- Where
- Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
- Age
- 18 years and over
- People
- 75 worldwide
- Run by
- AbbVie
See details and how to joinNCT04895436 · EU 2023-504599-10-00